ClinicalTrials.gg
CompletedNCT05328297Updated Jul 11, 2025Results posted

A Study of JNJ-55308942 in the Treatment of Bipolar Depression

A Phase 2 interventional study of JNJ-55308942 and Placebo in Bipolar Disorder, sponsored by Janssen Pharmaceutica N.V., Belgium. Completed at 44 sites in 4 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Janssen Pharmaceutica N.V., Belgium (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Bipolar Disorder by Johnson & Johnson — 2 open to participants now, 2 under way, 2 of them phase 3. Bipolar Disorder · Johnson & Johnson.

Enrollment
28th of 36
116 · median 300
Started
2022
the only one that year
Phase 2
Only one
of the 39
Registered
35th of 39
by date

Among the 39 studies in Bipolar Disorder by Johnson & Johnson, this one is the 28th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 2, and was the 35th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 39 studies in Bipolar Disorder by Johnson & Johnson are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Bipolar Disorder by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a primary (5th edition) (DSM-5) diagnosis of bipolar disorder (BD) (Type I or II) without current psychotic features, as confirmed by the mini international neuropsychiatric interview (MINI)
  • Medically stable on the basis of physical examination, medical history, and vital signs performed at screening. Any abnormalities must be consistent with the underlying illness in the study population. This determination must be recorded in the participant's source documents and initialed by the investigator
  • Have a (BMI) between 18.0 and 35.0 kilograms per meter square (kg/m\^2) inclusive (BMI = weight/height\^2)
  • A woman of (WOCBP) must have a negative highly sensitive serum pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) at screening and a negative urine pregnancy test before the first dose of study intervention

Exclusion criteria

Exclusion Criteria:

  • Currently meets the criteria for Manic Episode (ME) on the MINI
  • Received transcranial magnetic stimulation (TMS), any transcranial electrical stimulation, including transcranial direct current stimulation (tDCS), vagal nerve stimulation (VNS) and/or deep brain stimulation (DBS) within 6 weeks prior to randomization
  • History of moderate to severe cannabis misuse according to DSM-5 criteria within 6 months before screening
  • History of within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator is considered cured with minimal risk of recurrence)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    JNJ-55308942

    Participants will receive a JNJ-55308942 capsule once daily for 6 weeks.

    Drug: JNJ-55308942

  • Placebo comparator
    Placebo

    Participants will receive a matching placebo capsule once daily for 6 weeks.

    Drug: Placebo

Interventions

  • JNJ-55308942 capsules will be administered orally.

  • DrugPlacebo

    Matching placebo capsules will be administered orally.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Week 6

    Change from baseline in MADRS total score up to Week 6 were reported. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant (AD) treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

    Time frame: From Baseline (Day 1) up to Week 6

Secondary outcomes

  1. Change From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score up to Week 6

    Change from baseline in SHAPS total score up to Week 6 were reported. The SHAPS was a reliable, valid, and unidimensional instrument used to assess hedonic capacity in adults with Major Depressive Disorder. It is a 14-item, self-report tool with a completion time below 5 minutes. Each of the items had a set of 4 response categories: 1 = definitely agree/strongly agree, 2 = agree, 3 = disagree, and 4 = strongly disagree. The SHAPS total score was the sum of the 14 item scores, which ranged from 14 to 56. A higher SHAPS total score indicated higher levels of current anhedonia. Negative changes in the SHAPS total score indicated improvement.

    Time frame: From Baseline (Day 1) up to Week 6

  2. Change From Baseline in MADRS Total Score up to Week 6 (Genetic Subgroup Analysis)

    Genetic subgroup analysis included participants with bipolar depression and who were with P2RX7 Gain of Function single nucleotide polymorphism (P2RX7 GoF SNP) mutation genotype: heterozygous or homozygous. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

    Time frame: From Baseline (Day 1) up to Week 6

  3. Change From Baseline in MADRS Total Score up to Week 6 (Diagnosis Subgroup Analysis)

    Change from baseline in MADRS total score up to Week 6 (Diagnosis Subgroup Analysis) were reported. Diagnosis subgroup analysis included participants with bipolar type 1 or II. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

    Time frame: From Baseline (Day 1) up to Week 6

  4. Change From Baseline in MADRS Total Score up to Week 6 (Biomarker Subgroup Analysis)

    Biomarker subgroup analysis included specific (3-Marker Model \[3MM\]) biomarker profile: Yes or No. 3MM biomarker profile was defined as serum C-reactive protein \>3 mg/Liter(L) and soluble interleukin-6 receptor \>25 micrograms(mcg)/L or tumor necrosis factor \>4 nanograms(ng)/L at baseline. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Scale consist of 10 items each of which was scored from 0(item not present or normal) to 6(severe or continuous presence of the symptoms),with higher score indicating a more severe condition. MADRS total score was sum of scores from individual question items, ranged from 0 to 60,with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

    Time frame: From Baseline (Day 1) up to Week 6

  5. Number of Participants With Treatment-emergent Clinically Important Abnormalities in Vital Signs

    Vital signs parameters included pulse rate (abnormally low \[AL\]: \<50 beats per minute \[bpm\] and with \>15 bpm decrease from baseline and abnormally high \[AH\]: \>100 bpm and with \>15 bpm increase from baseline), Systolic blood pressure (SBP) (AL: \<90 millimeters of mercury \[mmHg\] and with \>20 mmHg decrease from baseline and AH: \>180 mmHg and with \>20 mmHg increase from baseline), Diastolic blood pressure (DBP) (AL: \<50 mmHg and with \>15 mmHg decrease from baseline and AH: \>105 mmHg and with \>15 mmHg increase from baseline) , temperature (AL:\<35.5 and AH:\>37.5 degree Celsius \[C\]), respiratory rate (AH :\>20 breaths per minute), and weight (AL: decrease from baseline \>7% and AH: increase from baseline \>7%). Weight was planned to analyzed at Weeks 6 and 8 only. Treatment-emergent concluded if postbaseline value was above/below upper/lower limit and baseline value was below/above the upper/lower limit.

    Time frame: Weeks 1, 2, 4, 6, and 8 (Follow-up/Early Withdrawal)

  6. Change From Baseline in Clinical Laboratory Values in Male Hormone: Inhibin B

    Change from baseline in clinical laboratory values in male hormone (Inhibin B) were reported.

    Time frame: Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)

  7. Change From Baseline in Clinical Laboratory Values in Male Hormone: Luteinizing Hormone

    Change from baseline in clinical laboratory values in male hormone (luteinizing hormone) were reported.

    Time frame: Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)

  8. Change From Baseline in Clinical Laboratory Values in Male Hormone: Prolactin

    Change from baseline in clinical laboratory values in male hormone (prolactin) were reported.

    Time frame: Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)

  9. Change From Baseline in Clinical Laboratory Values in Male Hormones: Sex Hormone Binding Globulin, Testosterone (Free), Testosterone (High Sensitivity), and Testosterone (Low Sensitivity)

    Change from baseline in clinical laboratory values in male hormones (sex hormone binding globulin, testosterone \[free\], testosterone \[high sensitivity\], and testosterone \[low sensitivity\]) were reported.

    Time frame: Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)

  10. Number of Participants With Abnormal Laboratory Values: Serum Chemistry

    Number of participants with abnormal laboratory values: serum chemistry were reported. It included: aspartate aminotransferase (high), alanine aminotransferase (high), bilirubin (high/low), and alkaline phosphatase (high/low). Only categories with data were reported.

    Time frame: Weeks 2, 4, 6, and 8 (Follow-up/Early Withdrawal)

  11. Number of Participants With Clinically Significant Abnormal Laboratory Values: Hematology

    Number of participants with clinically significant abnormal laboratory values: hematology were reported.

    Time frame: Weeks 2, 4, 6, and 8 (Follow-up/Early Withdrawal)

  12. Number of Participants With Clinically Significant Abnormal Laboratory Values: Urinalysis

    Number of participants with clinically significant abnormal laboratory values: urinalysis were reported.

    Time frame: Weeks 2, 4, 6, and 8 (Follow-up/Early Withdrawal)

  13. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs were reported. An adverse event (AE) is any untoward medical occurrence in a clinical study participants who administered a medicinal (investigational or non-investigational) product and does not necessarily have a causal relationship with the treatment. A TEAE defined as an AE that occurred at or after the first dose administration up to day of the last dose plus 30 days.

    Time frame: Day 1 (Week 0) up to 30 days after the last dose (up to 11 weeks)

  14. Number of Participants With Treatment-emergent Abnormalities in Electrocardiograms (ECGs)

    Number of participants with treatment-emergent abnormalities in ECGs were reported. It included ECG mean heart rate (abnormally low \[AL\]: \<50 and abnormally high \[AH\]: \>100 beats per minute \[bpm\]), PR Interval (AL: \<120 and AH: \>200 milliseconds \[msec\]), QRS Duration (AL: \<60 and AH: \>120 msec), and QT Interval (AL: \<200 and AH: \>500 msec). A treatment-emergent abnormalities in ECGs are defined as those abnormalities that occurred at or after the first dose administration.

    Time frame: Weeks 1, 2, 4, 6, and 8 (Follow-up/Early Withdrawal)

  15. Change From Baseline in Young Mania Rating Scale (YMRS) Total Score

    Change from baseline in YMRS total score were reported. The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS had 11 items : 4 items (irritability, speech, thought content, and disruptive/aggressive behavior) were graded on a scale of 0 to 8 and the remaining 7 items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) were graded on a scale of 0 to 4. Higher scores indicated greater symptom severity. Responses were summed to yield YMRS total score ranged from 0 to 60 , with higher scores reflecting greater severity of mania.

    Time frame: From Baseline (Day 1) up to Week 6

  16. Number of Participants Who Reported Suicidal Ideation (SI) or Suicidal Behavior (SB) Using With Columbia Suicide Severity Rating Scale (C-SSRS) Score

    C-SSRS is a clinician-rated instrument that reports severity of both suicidal ideation (SI) and suicidal behavior (SB). SI categories: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active SI with some intent to act, without specific plan), and 5 (active SI with specific plan and intent). SB categories: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt), and 10 (suicide). An additional category for non-suicide: non-suicidal self-injurious behavior. SI/SB was indicated by a "yes" answer to any of the listed categories. Score of 0 (no SI or SB) was assigned. Maximum score of 1 to 10 was assigned if suicidal ideation or behavior was present. Scoring was grouped into 3 categories: No SI/SB (0), SI (score 1 to 5), and SB (score 6 to 10), with higher scores indicating more severe ideation/behavior.

    Time frame: From Baseline (Day 1) up to Week 8

  17. Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score

    Change from baseline in CGI-S score were reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of mental illness exhibited by a participant, and rated on a scale of 1 to 7: 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in CGI-S score indicate improvement.

    Time frame: From Baseline (Day 1) up to Week 6

  18. Plasma Concentrations of JNJ-55308942

    Plasma concentrations of JNJ-55308942 were reported.

    Time frame: Predose, 1.5 hours and 4 hours post-dose on Week 0 (Day 1), Weeks 1 (Day 8), 2 (Day 15), 4 (Day 29), and 6 (Day 43)

  19. Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Score - Ability to Participate in Social Roles and Activities (APS) T-Scores

    Change from baseline in PROMIS score - ability to participate in social roles and activities T-Scores were reported. The PROMIS - APS item bank assessed the perceived ability to perform one's usual social roles and activities. The item bank did not use a time frame (for example, over the past seven days) when assessing the APS. The Short Form 4a included 4 items that represent this concept. Each question had 5 response options ranging in value from 1 to 5 with higher scores indicating better social function. The total raw score for the short form was calculated by summing the values of the response to each question, so for the 4-item form, the lowest possible raw score was 4; the highest possible raw score was 20. The total raw score was converted to a T score with a mean of 50 and a standard deviation of 10. Higher T-scores indicate better social function.

    Time frame: Baseline (Day 1), Weeks 1, 2, 3, 4, 5, and 6

  20. Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score

    Change from baseline in PHQ-9 total score were reported. PHQ-9 is 9-item, self-report scale assessed depressive symptoms. Each item was rated on 4-point scale (0=Not at all, 1=several days, 2=more than half days, 3=nearly every day. The participant's item responses were summed to provide PHQ-9 total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms.

    Time frame: Baseline (Day 1), Weeks 1, 2, 3, 4, 5, and 6

  21. Change From Baseline in Generalized Anxiety Disorder 7 (GAD-7) Total Score

    Change from baseline in GAD-7 total score were reported. GAD-7 is a brief and validated 7-item self-reported questionnaire for assessment of overall GAD. Participants responded to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day, with a higher score representing a more severe condition. Item responses were summed to yield GAD-7 total score which ranged of 0 to 21, where higher scores indicated more anxiety.

    Time frame: Baseline (Day 1), Weeks 2, 4, and 6

  22. Number of Participants Who Achieved Response at Week 6

    Number of participants who achieved response at Week 6 were reported. Response was defined as greater than or equal to (\>=)50% improvement in MADRS total score from baseline. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

    Time frame: Week 6

  23. Number of Participants Who Achieved Remission at Week 6

    Number of participants who achieved remission at Week 6 were reported. Remission was defined as MADRS total score \<=12. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

    Time frame: Week 6

  24. Change From Baseline in MADRS Total Score up to Week 6 (Subgroup of Participants With Messenger Ribonucleic Acid [mRNA] Transcript Levels)

    Change from baseline in MADRS total score up to Week 6 (subgroup of participants with mRNA transcript levels) was planned to be reported. Subgroup included participants with mRNA transcript levels at baseline that exceeded the medium level for both P2RX7 and IL-1-beta. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

    Time frame: From Baseline (Day 1) up to Week 6

  25. Change From Baseline in MADRS Total Score up to Week 6 (Concomitant Medication Subgroup Analysis)

    Change from baseline in MADRS total score up to Week 6 (concomitant medication subgroup analysis) was reported. Concomitant medication subgroup analysis included subjects with BD not taking any mood stabilizer or antipsychotic, taking a mood stabilizer alone, taking antipsychotic alone, and taking a combination of mood stabilizer and an antipsychotic. MADRS measures depression severity, detects changes due to AD treatment. It consists of 10 items (evaluate apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed to total possible score of 0 to 60. Higher scores indicate more severe conditions. Negative change in score indicates improvement.

    Time frame: From Baseline (Day 1) up to Week 6

07

Results

Posted Jul 11, 2025

Participant flow

Participant flow — Overall Study
MilestoneJNJ-55308942Placebo
Started5561
Treated (safety analysis set)5460
Completed4250
Not completed1311
Withdrew: Adverse event57
Withdrew: Withdrawal by subject43
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up10
Withdrew: Protocol violation10
Withdrew: Randomized but not treated11

Outcome measures

PrimaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Week 6

Change from baseline in MADRS total score up to Week 6 were reported. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant (AD) treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

Time frame:
From Baseline (Day 1) up to Week 6
Reported as:
Mean · Units on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Week 6
Units on a scaleJNJ-55308942Placebo
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Week 6-16.0 ± 10.43-15.4 ± 9.81
Statistical analysis
  • JNJ-55308942 vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = =0.438 · Least square mean difference: -0.3 · 80% CI -2.84 to 2.23
SecondaryChange From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score up to Week 6

Change from baseline in SHAPS total score up to Week 6 were reported. The SHAPS was a reliable, valid, and unidimensional instrument used to assess hedonic capacity in adults with Major Depressive Disorder. It is a 14-item, self-report tool with a completion time below 5 minutes. Each of the items had a set of 4 response categories: 1 = definitely agree/strongly agree, 2 = agree, 3 = disagree, and 4 = strongly disagree. The SHAPS total score was the sum of the 14 item scores, which ranged from 14 to 56. A higher SHAPS total score indicated higher levels of current anhedonia. Negative changes in the SHAPS total score indicated improvement.

Time frame:
From Baseline (Day 1) up to Week 6
Reported as:
Mean · Units on a scale
Change From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score up to Week 6
Units on a scaleJNJ-55308942Placebo
Change From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score up to Week 6-8.2 ± 6.87-8.3 ± 8.69
SecondaryChange From Baseline in MADRS Total Score up to Week 6 (Genetic Subgroup Analysis)

Genetic subgroup analysis included participants with bipolar depression and who were with P2RX7 Gain of Function single nucleotide polymorphism (P2RX7 GoF SNP) mutation genotype: heterozygous or homozygous. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

Time frame:
From Baseline (Day 1) up to Week 6
Reported as:
Mean · Units on a scale
Change From Baseline in MADRS Total Score up to Week 6 (Genetic Subgroup Analysis)
Units on a scaleJNJ-55308942Placebo
P2RX7 GoF SNP mutation genotype: Heterozygous-15.2 ± 9.45-16.5 ± 10.22
P2RX7 GoF SNP mutation genotype: Homozygous-18.2 ± 13.06-13.1 ± 8.75
SecondaryChange From Baseline in MADRS Total Score up to Week 6 (Diagnosis Subgroup Analysis)

Change from baseline in MADRS total score up to Week 6 (Diagnosis Subgroup Analysis) were reported. Diagnosis subgroup analysis included participants with bipolar type 1 or II. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

Time frame:
From Baseline (Day 1) up to Week 6
Reported as:
Mean · Units on a scale
Change From Baseline in MADRS Total Score up to Week 6 (Diagnosis Subgroup Analysis)
Units on a scaleJNJ-55308942Placebo
Bipolar type I-15.5 ± 11.02-15.3 ± 10.06
Bipolar type II-17.7 ± 8.20-15.7 ± 9.47
SecondaryChange From Baseline in MADRS Total Score up to Week 6 (Biomarker Subgroup Analysis)

Biomarker subgroup analysis included specific (3-Marker Model \[3MM\]) biomarker profile: Yes or No. 3MM biomarker profile was defined as serum C-reactive protein \>3 mg/Liter(L) and soluble interleukin-6 receptor \>25 micrograms(mcg)/L or tumor necrosis factor \>4 nanograms(ng)/L at baseline. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Scale consist of 10 items each of which was scored from 0(item not present or normal) to 6(severe or continuous presence of the symptoms),with higher score indicating a more severe condition. MADRS total score was sum of scores from individual question items, ranged from 0 to 60,with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

Time frame:
From Baseline (Day 1) up to Week 6
Reported as:
Mean · Units on a scale
Change From Baseline in MADRS Total Score up to Week 6 (Biomarker Subgroup Analysis)
Units on a scaleJNJ-55308942Placebo
3MM biomarker profile: Yes-12.5 ± 9.04-13.9 ± 10.77
3MM biomarker profile: No-17.2 ± 10.75-16.6 ± 9.17
SecondaryNumber of Participants With Treatment-emergent Clinically Important Abnormalities in Vital Signs

Vital signs parameters included pulse rate (abnormally low \[AL\]: \<50 beats per minute \[bpm\] and with \>15 bpm decrease from baseline and abnormally high \[AH\]: \>100 bpm and with \>15 bpm increase from baseline), Systolic blood pressure (SBP) (AL: \<90 millimeters of mercury \[mmHg\] and with \>20 mmHg decrease from baseline and AH: \>180 mmHg and with \>20 mmHg increase from baseline), Diastolic blood pressure (DBP) (AL: \<50 mmHg and with \>15 mmHg decrease from baseline and AH: \>105 mmHg and with \>15 mmHg increase from baseline) , temperature (AL:\<35.5 and AH:\>37.5 degree Celsius \[C\]), respiratory rate (AH :\>20 breaths per minute), and weight (AL: decrease from baseline \>7% and AH: increase from baseline \>7%). Weight was planned to analyzed at Weeks 6 and 8 only. Treatment-emergent concluded if postbaseline value was above/below upper/lower limit and baseline value was below/above the upper/lower limit.

Time frame:
Weeks 1, 2, 4, 6, and 8 (Follow-up/Early Withdrawal)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Clinically Important Abnormalities in Vital Signs
ParticipantsJNJ-55308942Placebo
Pulse (beats per minutes [bpm]): <50 bpm and with >15 bpm decrease from baseline: Week 10 (9.04 to —)0 (10.77 to —)
Pulse (bpm): >100 bpm and with >15 bpm increase from baseline: Week 10 (10.75 to —)0 (9.17 to —)
SBP (millimeters of mercury [mmHg]): <90 mmHg and with >20 mmHg decrease from baseline: Week 100
SBP (mmHg): >180 mmHg and with >20 mmHg increase from baseline: Week 100
DBP (mmHg): <50 mmHg and with >15 mmHg decrease from baseline : Week 100
DBP (mmHg): >105 mmHg and with >15 mmHg increase from baseline: Week 100
Temperature (degree Celsius [C]): <35.5 degree C: Week 100
Temperature (degree C): >37.5 degree C: Week 100
Respiratory Rate: >20 breaths per minute: Week 100
Pulse: <50 bpm and with >15 bpm decrease from baseline: Week 200
Pulse: >100 bpm and with >15 bpm increase from baseline: Week 200
SBP:<90 mmHg and with >20 mmHg decrease from baseline: Week 200
SBP: >180 mmHg and with >20 mmHg increase from baseline: Week 200
DBP: <50 mmHg and with >15 mmHg decrease from baseline: Week 200
DBP: >105 mmHg and with >15 mmHg increase from baseline: Week 200
Temperature (degree C): <35.5 degree C: Week 200
Temperature (degree C): >37.5 degree C: Week 200
Respiratory Rate: >20 breaths per minute: Week 201
Pulse (bpm): <50 bpm and with >15 bpm decrease from baseline: Week 400
Pulse (bpm): >100 bpm and with >15 bpm increase from baseline: Week 400
SBP (mmHg): <90 mmHg and with >20 mmHg decrease from baseline: Week 400
SBP (mmHg): >180 mmHg and with >20 mmHg increase from baseline: Week 400
DBP (mmHg): <50 mmHg and with >15 mmHg decrease from baseline: Week 400
DBP (mmHg): <105 mmHg and with >15 mmHg increase from baseline: Week 400
Temperature (degree C): <35.5 degree C: Week 400
Temperature (degree C): >37.5 degree C: Week 400
Respiratory Rate: >20 breaths per minute: Week 400
Pulse: <50 bpm and with >15 bpm decrease from baseline: Week 600
Pulse: <100 bpm and with >15 bpm increase from baseline: Week 600
SBP (mmHg): <90 mmHg and with >20 mmHg decrease from baseline: Week 600
SBP (mmHg): >180 mmHg and with >20 mmHg increase from baseline: Week 600
DBP (mmHg): <50 mmHg and with >15 mmHg decrease from baseline: Week 600
DBP (mmHg): >105 mmHg and with >15 mmHg increase from baseline: Week 600
Temperature (C): <35.5 degree C: Week 600
Temperature (degree C): <37.5 degree C: Week 600
Respiratory Rate (breaths/min): >20 breaths per minute: Week 600
Weight (kg): Decrease from baseline >7%: Week 600
Weight (kg): Increase from baseline >7%: Week 601
Pulse: <50 bpm and with >15 bpm decrease from baseline: Follow-up (Week 8)00
Pulse: >100 bpm and with >15 bpm increase from baseline: Follow-up (Week 8)10
SBP (mmHg): <90mmHg and with >20 mmHg decrease from baseline: Follow-up (Week 8)00
SBP (mmHg):>180mmHg and with >20 mmHg increase from baseline: Follow-up (Week 8)01
DBP (mmHg): <50mmHg and with >15mmHg decrease from baseline: Follow-up (Week 8)00
DBP (mmHg):>105mmHg and with >15mmHg increase from baseline: Follow-up (Week 8)01
Temperature (C): <35.5 degree C: Follow-up (Week 8)00
Temperature (C): >37.5 degree C: Follow-up (Week 8)00
Respiratory Rate (breaths/min): >20 breaths per minute: Follow-up (Week 8)00
Weight (kg): Decrease from baseline >7%: Follow-up (Week 8)10
Weight (kg): Increase from baseline >7%: Follow-up (Week 8)02
SecondaryChange From Baseline in Clinical Laboratory Values in Male Hormone: Inhibin B

Change from baseline in clinical laboratory values in male hormone (Inhibin B) were reported.

Time frame:
Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)
Reported as:
Mean · nanograms per liter (ng/L)
Change From Baseline in Clinical Laboratory Values in Male Hormone: Inhibin B
nanograms per liter (ng/L)JNJ-55308942Placebo
Week 4-5.9 ± 30.453.1 ± 22.15
Week 6-2.1 ± 30.02-1.8 ± 31.09
Week 8-1.2 ± 28.257.3 ± 19.60
SecondaryChange From Baseline in Clinical Laboratory Values in Male Hormone: Luteinizing Hormone

Change from baseline in clinical laboratory values in male hormone (luteinizing hormone) were reported.

Time frame:
Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)
Reported as:
Mean · International units per liter (IU/L)
Change From Baseline in Clinical Laboratory Values in Male Hormone: Luteinizing Hormone
International units per liter (IU/L)JNJ-55308942Placebo
Week 40.15 ± 1.8140.29 ± 1.513
Week 6-0.11 ± 1.6770.63 ± 2.719
Week 8-0.35 ± 1.6380.84 ± 2.103
SecondaryChange From Baseline in Clinical Laboratory Values in Male Hormone: Prolactin

Change from baseline in clinical laboratory values in male hormone (prolactin) were reported.

Time frame:
Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)
Reported as:
Mean · micrograms per liter (mcg/L)
Change From Baseline in Clinical Laboratory Values in Male Hormone: Prolactin
micrograms per liter (mcg/L)JNJ-55308942Placebo
Week 40.347 ± 2.43601.803 ± 3.6211
Week 60.551 ± 3.15751.465 ± 5.3742
Week 8-0.160 ± 3.86221.748 ± 3.9231
SecondaryChange From Baseline in Clinical Laboratory Values in Male Hormones: Sex Hormone Binding Globulin, Testosterone (Free), Testosterone (High Sensitivity), and Testosterone (Low Sensitivity)

Change from baseline in clinical laboratory values in male hormones (sex hormone binding globulin, testosterone \[free\], testosterone \[high sensitivity\], and testosterone \[low sensitivity\]) were reported.

Time frame:
Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)
Reported as:
Mean · nanomoles per liter (nmol/L)
Change From Baseline in Clinical Laboratory Values in Male Hormones: Sex Hormone Binding Globulin, Testosterone (Free), Testosterone (High Sensitivity), and Testosterone (Low Sensitivity)
nanomoles per liter (nmol/L)JNJ-55308942Placebo
Sex Hormone Binding Globulin: Week 4-1.976 ± 7.1297-0.574 ± 8.5796
Sex Hormone Binding Globulin: Week 6-4.020 ± 7.4992-0.274 ± 9.2454
Sex Hormone Binding Globulin: Week 8-2.520 ± 7.84891.058 ± 6.6109
Testosterone, Free: Week 40.005 ± 0.06770.030 ± 0.0995
Testosterone, Free: Week 6-0.010 ± 0.07310.037 ± 0.1084
Testosterone, Free: Week 80.031 ± 0.07630.046 ± 0.0877
Testosterone, High Sensitivity: Week 4-0.797 ± 3.32710.357 ± 5.5917
Testosterone, High Sensitivity: Week 6-1.262 ± 3.68070.842 ± 5.6815
Testosterone, High Sensitivity: Week 80.604 ± 3.77181.416 ± 4.3083
Testosterone, Low Sensitivity: Week 4-0.791 ± 3.88860.854 ± 5.9616
Testosterone, Low Sensitivity: Week 6-1.532 ± 4.52031.380 ± 5.9515
Testosterone, Low Sensitivity: Week 81.116 ± 4.84521.728 ± 4.6578
SecondaryNumber of Participants With Abnormal Laboratory Values: Serum Chemistry

Number of participants with abnormal laboratory values: serum chemistry were reported. It included: aspartate aminotransferase (high), alanine aminotransferase (high), bilirubin (high/low), and alkaline phosphatase (high/low). Only categories with data were reported.

Time frame:
Weeks 2, 4, 6, and 8 (Follow-up/Early Withdrawal)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Values: Serum Chemistry
ParticipantsJNJ-55308942Placebo
Aspartate Aminotransferase (High): Week 222
Aspartate Aminotransferase (High): Week 402
Aspartate Aminotransferase (High): Week 610
Aspartate Aminotransferase (High): Week 802
Alanine Aminotransferase (High): Week 213
Alanine Aminotransferase (High): Week 423
Alanine Aminotransferase (High): Week 621
Alanine Aminotransferase (High): Week 812
Bilirubin (Low): Week 249
Bilirubin (High): Week 210
Bilirubin (Low): Week 487
Bilirubin (Low): Week 654
Bilirubin (High): Week 620
Bilirubin (Low): Week 835
Bilirubin (High): Week 810
Alkaline Phosphatase (Low): Week 210
Alkaline Phosphatase (High): Week 235
Alkaline Phosphatase (Low): Week 410
Alkaline Phosphatase (High): Week 403
Alkaline Phosphatase (Low): Week 610
Alkaline Phosphatase (High): Week 616
Alkaline Phosphatase (Low): Week 810
Alkaline Phosphatase (High): Week 845
SecondaryNumber of Participants With Clinically Significant Abnormal Laboratory Values: Hematology

Number of participants with clinically significant abnormal laboratory values: hematology were reported.

Time frame:
Weeks 2, 4, 6, and 8 (Follow-up/Early Withdrawal)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Laboratory Values: Hematology
ParticipantsJNJ-55308942Placebo
Week 200
Week 400
Week 600
Week 800
SecondaryNumber of Participants With Clinically Significant Abnormal Laboratory Values: Urinalysis

Number of participants with clinically significant abnormal laboratory values: urinalysis were reported.

Time frame:
Weeks 2, 4, 6, and 8 (Follow-up/Early Withdrawal)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Laboratory Values: Urinalysis
ParticipantsJNJ-55308942Placebo
Week 200
Week 400
Week 600
Week 800
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs were reported. An adverse event (AE) is any untoward medical occurrence in a clinical study participants who administered a medicinal (investigational or non-investigational) product and does not necessarily have a causal relationship with the treatment. A TEAE defined as an AE that occurred at or after the first dose administration up to day of the last dose plus 30 days.

Time frame:
Day 1 (Week 0) up to 30 days after the last dose (up to 11 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsJNJ-55308942Placebo
Number of Participants With Treatment-emergent Adverse Events (TEAEs)2228
SecondaryNumber of Participants With Treatment-emergent Abnormalities in Electrocardiograms (ECGs)

Number of participants with treatment-emergent abnormalities in ECGs were reported. It included ECG mean heart rate (abnormally low \[AL\]: \<50 and abnormally high \[AH\]: \>100 beats per minute \[bpm\]), PR Interval (AL: \<120 and AH: \>200 milliseconds \[msec\]), QRS Duration (AL: \<60 and AH: \>120 msec), and QT Interval (AL: \<200 and AH: \>500 msec). A treatment-emergent abnormalities in ECGs are defined as those abnormalities that occurred at or after the first dose administration.

Time frame:
Weeks 1, 2, 4, 6, and 8 (Follow-up/Early Withdrawal)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Abnormalities in Electrocardiograms (ECGs)
ParticipantsJNJ-55308942Placebo
ECG Mean Heart Rate: <50 bpm: Week 110
ECG Mean Heart Rate: >100 bpm: Week 100
PR Interval: <120 msec: Week 101
PR Interval: >200 msec: Week 110
QRS Duration: <60 msec: Week 101
QRS Duration: >120 msec: Week 110
QT Interval: <200 msec: Week 100
QT Interval: >500 msec: Week 100
ECG Mean Heart Rate: <50 bpm: Week 200
ECG Mean Heart Rate: >100 bpm: Week 211
PR Interval: <120 msec: Week 200
PR Interval: >200 msec: Week 212
QRS Duration: <60 msec: Week 201
QRS Duration: >120 msec: Week 201
QT Interval: <200 msec: Week 200
QT Interval: >500 msec: Week 200
ECG Mean Heart Rate: <50 bpm: Week 400
ECG Mean Heart Rate: >100 bpm: Week 410
PR Interval: <120 msec: Week 401
PR Interval: >200 msec: Week 400
QRS Duration: <60 msec: Week 401
QRS Duration: >120 msec: Week 410
QT Interval: <200 msec: Week 400
QT Interval: >500 msec: Week 400
ECG Mean Heart Rate: <50 bpm: Week 600
ECG Mean Heart Rate: >100 bpm: Week 600
PR Interval: <120 msec: Week 600
PR Interval: >200 msec: Week 600
QRS Duration: <60 msec: Week 604
QRS Duration: >120 msec: Week 600
QT Interval: <200 msec: Week 600
QT Interval: >500 msec: Week 600
ECG Mean Heart Rate: <50 bpm: Week 800
ECG Mean Heart Rate: >100 bpm: Week 800
PR Interval: <120 msec: Week 810
PR Interval: >200 msec: Week 800
QRS Duration: <60 msec: Week 812
QRS Duration: >120 msec: Week 801
QT Interval: <200 msec: Week 800
QT Interval: >500 msec: Week 800
SecondaryChange From Baseline in Young Mania Rating Scale (YMRS) Total Score

Change from baseline in YMRS total score were reported. The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS had 11 items : 4 items (irritability, speech, thought content, and disruptive/aggressive behavior) were graded on a scale of 0 to 8 and the remaining 7 items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) were graded on a scale of 0 to 4. Higher scores indicated greater symptom severity. Responses were summed to yield YMRS total score ranged from 0 to 60 , with higher scores reflecting greater severity of mania.

Time frame:
From Baseline (Day 1) up to Week 6
Reported as:
Mean · Units on a scale
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score
Units on a scaleJNJ-55308942Placebo
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score-1.2 ± 2.23-1.1 ± 1.81
SecondaryNumber of Participants Who Reported Suicidal Ideation (SI) or Suicidal Behavior (SB) Using With Columbia Suicide Severity Rating Scale (C-SSRS) Score

C-SSRS is a clinician-rated instrument that reports severity of both suicidal ideation (SI) and suicidal behavior (SB). SI categories: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active SI with some intent to act, without specific plan), and 5 (active SI with specific plan and intent). SB categories: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt), and 10 (suicide). An additional category for non-suicide: non-suicidal self-injurious behavior. SI/SB was indicated by a "yes" answer to any of the listed categories. Score of 0 (no SI or SB) was assigned. Maximum score of 1 to 10 was assigned if suicidal ideation or behavior was present. Scoring was grouped into 3 categories: No SI/SB (0), SI (score 1 to 5), and SB (score 6 to 10), with higher scores indicating more severe ideation/behavior.

Time frame:
From Baseline (Day 1) up to Week 8
Reported as:
Count of participants · Participants
Number of Participants Who Reported Suicidal Ideation (SI) or Suicidal Behavior (SB) Using With Columbia Suicide Severity Rating Scale (C-SSRS) Score
ParticipantsJNJ-55308942Placebo
Suicidal ideation36
Suicidal behavior10
No SI/SB49 (2.23 to —)53 (1.81 to —)
SecondaryChange From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score

Change from baseline in CGI-S score were reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of mental illness exhibited by a participant, and rated on a scale of 1 to 7: 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in CGI-S score indicate improvement.

Time frame:
From Baseline (Day 1) up to Week 6
Reported as:
Mean · Units on a scale
Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score
Units on a scaleJNJ-55308942Placebo
Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score-1.9 ± 1.49-1.7 ± 1.32
SecondaryPlasma Concentrations of JNJ-55308942

Plasma concentrations of JNJ-55308942 were reported.

Time frame:
Predose, 1.5 hours and 4 hours post-dose on Week 0 (Day 1), Weeks 1 (Day 8), 2 (Day 15), 4 (Day 29), and 6 (Day 43)
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Plasma Concentrations of JNJ-55308942
Nanograms per milliliter (ng/mL)JNJ-55308942
Week 0 (Day 1): Predose0.00 ± 0.000
Week 0 (Day 1): 1.5 hours postdose406.13 ± 162.407
Week 0 (Day 1): 4 hours postdose407.72 ± 133.461
Week 1 (Day 8): Predose531.20 ± 200.351
Week 1 (Day 8): 1.5 hours postdose868.01 ± 296.255
Week 1 (Day 8): 4 hours postdose892.54 ± 219.210
Week 2 (Day 15): Predose561.32 ± 194.184
Week 2 (Day 15): 1.5 hours postdose930.59 ± 265.581
Week 2 (Day 15): 4 hours postdose919.86 ± 213.028
Week 4 (Day 29): Predose528.90 ± 144.580
Week 4 (Day 29): 1.5 hours postdose885.50 ± 249.562
Week 4 (Day 29): 4 hours postdose872.80 ± 208.734
Week 6 (Day 43): Predose535.80 ± 160.568
Week 6 (Day 43): 1.5 hours postdose862.31 ± 240.540
Week 6 (Day 43): 4 hours postdose883.51 ± 209.413
SecondaryChange From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Score - Ability to Participate in Social Roles and Activities (APS) T-Scores

Change from baseline in PROMIS score - ability to participate in social roles and activities T-Scores were reported. The PROMIS - APS item bank assessed the perceived ability to perform one's usual social roles and activities. The item bank did not use a time frame (for example, over the past seven days) when assessing the APS. The Short Form 4a included 4 items that represent this concept. Each question had 5 response options ranging in value from 1 to 5 with higher scores indicating better social function. The total raw score for the short form was calculated by summing the values of the response to each question, so for the 4-item form, the lowest possible raw score was 4; the highest possible raw score was 20. The total raw score was converted to a T score with a mean of 50 and a standard deviation of 10. Higher T-scores indicate better social function.

Time frame:
Baseline (Day 1), Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Mean · T-score
Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Score - Ability to Participate in Social Roles and Activities (APS) T-Scores
T-scoreJNJ-55308942Placebo
PROMIS-APS T-score: Week 12.51 ± 5.6821.69 ± 6.859
PROMIS-APS T-score: Week 25.33 ± 6.9014.49 ± 9.174
PROMIS-APS T-score: Week 36.52 ± 8.2265.00 ± 8.884
PROMIS-APS T-score: Week 49.12 ± 9.0186.07 ± 8.369
PROMIS-APS T-score: Week 59.47 ± 8.2484.90 ± 9.296
PROMIS-APS T-score: Week 610.50 ± 8.2116.12 ± 8.412
SecondaryChange From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score

Change from baseline in PHQ-9 total score were reported. PHQ-9 is 9-item, self-report scale assessed depressive symptoms. Each item was rated on 4-point scale (0=Not at all, 1=several days, 2=more than half days, 3=nearly every day. The participant's item responses were summed to provide PHQ-9 total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms.

Time frame:
Baseline (Day 1), Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Mean · Units on a scale
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score
Units on a scaleJNJ-55308942Placebo
Week 1-2.8 ± 4.24-3.1 ± 5.45
Week 2-5.2 ± 5.64-4.7 ± 6.63
Week 3-6.4 ± 6.25-5.1 ± 6.90
Week 4-7.0 ± 6.38-6.1 ± 6.81
Week 5-8.2 ± 6.59-5.2 ± 7.21
Week 6-9.0 ± 6.79-7.0 ± 7.41
SecondaryChange From Baseline in Generalized Anxiety Disorder 7 (GAD-7) Total Score

Change from baseline in GAD-7 total score were reported. GAD-7 is a brief and validated 7-item self-reported questionnaire for assessment of overall GAD. Participants responded to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day, with a higher score representing a more severe condition. Item responses were summed to yield GAD-7 total score which ranged of 0 to 21, where higher scores indicated more anxiety.

Time frame:
Baseline (Day 1), Weeks 2, 4, and 6
Reported as:
Mean · Units on a scale
Change From Baseline in Generalized Anxiety Disorder 7 (GAD-7) Total Score
Units on a scaleJNJ-55308942Placebo
Week 2-3.8 ± 5.08-4.2 ± 5.76
Week 4-5.0 ± 6.59-4.5 ± 5.14
Week 6-5.7 ± 6.21-5.7 ± 5.77
SecondaryNumber of Participants Who Achieved Response at Week 6

Number of participants who achieved response at Week 6 were reported. Response was defined as greater than or equal to (\>=)50% improvement in MADRS total score from baseline. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Response at Week 6
ParticipantsJNJ-55308942Placebo
Number of Participants Who Achieved Response at Week 627 (6.21 to —)31 (5.77 to —)
SecondaryNumber of Participants Who Achieved Remission at Week 6

Number of participants who achieved remission at Week 6 were reported. Remission was defined as MADRS total score \<=12. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Remission at Week 6
ParticipantsJNJ-55308942Placebo
Number of Participants Who Achieved Remission at Week 625 (6.21 to —)30 (5.77 to —)
SecondaryChange From Baseline in MADRS Total Score up to Week 6 (Subgroup of Participants With Messenger Ribonucleic Acid [mRNA] Transcript Levels)

Change from baseline in MADRS total score up to Week 6 (subgroup of participants with mRNA transcript levels) was planned to be reported. Subgroup included participants with mRNA transcript levels at baseline that exceeded the medium level for both P2RX7 and IL-1-beta. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.

Time frame:
From Baseline (Day 1) up to Week 6
Reported as:
Mean · Units on a scale
Change From Baseline in MADRS Total Score up to Week 6 (Subgroup of Participants With Messenger Ribonucleic Acid [mRNA] Transcript Levels)
Units on a scaleJNJ-55308942Placebo
Change From Baseline in MADRS Total Score up to Week 6 (Subgroup of Participants With Messenger Ribonucleic Acid [mRNA] Transcript Levels)NA ± NANA ± NA
SecondaryChange From Baseline in MADRS Total Score up to Week 6 (Concomitant Medication Subgroup Analysis)

Change from baseline in MADRS total score up to Week 6 (concomitant medication subgroup analysis) was reported. Concomitant medication subgroup analysis included subjects with BD not taking any mood stabilizer or antipsychotic, taking a mood stabilizer alone, taking antipsychotic alone, and taking a combination of mood stabilizer and an antipsychotic. MADRS measures depression severity, detects changes due to AD treatment. It consists of 10 items (evaluate apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed to total possible score of 0 to 60. Higher scores indicate more severe conditions. Negative change in score indicates improvement.

Time frame:
From Baseline (Day 1) up to Week 6
Reported as:
Mean · Units on a scale
Change From Baseline in MADRS Total Score up to Week 6 (Concomitant Medication Subgroup Analysis)
Units on a scaleJNJ-55308942Placebo
Concomitant medication status: Not taking any mood stabilizer or antipsychotic-15.5 ± 13.18-16.2 ± 9.69
Concomitant medication status: Taking a mood stabilizer alone-16.3 ± 9.82-15.6 ± 9.47
Concomitant medication status: Taking an antipsychotic alone-13.0 ± NA5.0 ± NA
Concomitant medication status: Taking a combination of a mood stabilizer and an antipsychotic-13.0 ± NA—

Adverse events

Collected over All-cause mortality: From screening (-28 days) up to end of study (up to 12 weeks); SAEs and Other AEs: From Day 1 (Week 0) up to 30 days after the last dose (up to 11 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
JNJ-553089420/55 (0%)2/54 (3.7%)6/54 (11.1%)
Placebo0/61 (0%)3/60 (5%)10/60 (16.7%)
Most frequent serious events
Most frequent serious events
EventJNJ-55308942Placebo
DepressionPsychiatric disorders1/540/60
Suicide AttemptPsychiatric disorders1/540/60
CholelithiasisHepatobiliary disorders0/541/60
Intentional OverdoseInjury, poisoning and procedural complications0/541/60
Behaviour DisorderPsychiatric disorders0/541/60
ManiaPsychiatric disorders0/541/60
Most frequent other events
Most frequent other events
EventJNJ-55308942Placebo
NauseaGastrointestinal disorders4/545/60
HeadacheNervous system disorders3/544/60
DiarrhoeaGastrointestinal disorders2/543/60
VomitingGastrointestinal disorders1/543/60

Baseline characteristics

Safety analysis set included all randomized participants who received at least 1 dose of study treatment in the double-blind (DB) treatment phase.

Age, Continuous
Age, Continuous(years)JNJ-55308942PlaceboTotal
Mean39.28 ± 13.60340.18 ± 12.66439.75 ± 13.067
Sex: Female, Male
Sex: Female, Male(Participants)JNJ-55308942PlaceboTotal
Female383371
Male162743
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)JNJ-55308942PlaceboTotal
Hispanic or Latino369
Not Hispanic or Latino5053103
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)JNJ-55308942PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander112
Black or African American8816
White445094
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(Participants)JNJ-55308942PlaceboTotal
Canada101
Poland303060
Spain257
United States212546
08

Study locations

44 sites
  • UAB Huntsville Regional Medical Campus
    Huntsville, Alabama 35801, United States
  • Preferred Research Partners
    Little Rock, Arkansas 72211, United States
  • Synergy East
    Lemon Grove, California 91945, United States
  • Collaborative NeuroScience Network
    Torrance, California 90504, United States
  • Clinical Neuroscience Solutions Inc
    Jacksonville, Florida 32256, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 23801, United States
  • Psychiatric Medicine Associates LLC
    Skokie, Illinois 60076, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Richard H. Weisler, MD & Associates
    Raleigh, North Carolina 27609-9148, United States
  • Case Western Reserve School of Medicine
    Cleveland, Ohio 44106, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Clinical NeuroScience Solutions Inc
    Memphis, Tennessee 38119, United States
  • The University of Texas at Austin Department of Psychiatry, Dell Medical School
    Austin, Texas 78712-1873, United States
  • North Texas Clinical Trials
    Fort Worth, Texas 76104, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77054, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • The Medical Arts Health Research Group
    West Vancouver, British Columbia V7T 1C5, Canada
  • Chatham-Kent Clinical Trials Research Centre
    Chatham, Ontario N7L 1C1, Canada
  • Uniwersytecki Szpital Kliniczny w Bialymstoku Klinika Psychiatrii
    Bialystok, 15 272, Poland
  • PROMENTE Sp. z o.o.
    Bydgoszcz, 85-133, Poland
  • Centrum Badan Klinicznych PI House sp z o o
    Gdansk, 80 546, Poland
  • Specjalistyczna Praktyka Lekarska Piotr Zalitacz
    Gorlice, 30073, Poland
  • Centrum Medyczne Care Clinic Katowice
    Katowice, 40-568, Poland
  • Indywidualna Praktyka Lekarska Kinga Bobinska
    Lodz, 90-009, Poland
  • Filip Rybakowski Specjalistyczna Praktyka Lekarska
    Poznan, 60 744, Poland
  • Centrum Medyczne HCP Sp. z o.o. Osrodek Badan Klinicznych
    Poznan, 61-485, Poland
  • Samodzielny Publiczny Zespol Lecznictwa Psychiatrycznego w Siemianowicach Slaskich
    Siemianowice Śląskie, 41-100, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska Agnieszka Remlinger Molenda
    Suchy Las, 62-002, Poland
  • Szpital Nowowiejski Osrodek Badan Klinicznych
    Warsaw, 00-774, Poland
  • Instytut Psychiatrii I Neurologii
    Warsaw, 02957, Poland
  • Przychodnia Lekarsko-Psychologiczna Persona
    Wroclaw, 50-227, Poland
  • Ginemedica Sp. z o.o.
    Wroclaw, 50-414, Poland
  • Hosp. Del Mar
    Barcelona, 08003, Spain
  • Institucion Hosp Hestia Palau
    Barcelona, 08025, Spain
  • Hosp Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hosp. Univ. Ramon Y Cajal
    Madrid, 28034, Spain
  • Centro Salud Mental La Eria
    Oviedo, 33013, Spain
  • Clinica Univ. de Navarra
    Pamplona, 31008, Spain
  • Hosp. El Bierzo
    Ponferrada, 24404, Spain
  • Hosp. Univ. I Politecni La Fe
    Valencia, 46026, Spain
  • Hosp. Alvaro Cunqueiro
    Vigo, 36213, Spain
  • Hosp. Psiquiatrico Alava
    Vitoria-Gasteiz, 1006, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in May 2024, 23 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2022
First posted
Apr 14, 2022
StartActual
Jun 3, 2022
Primary completionActual
May 17, 2024
CompletionActual
May 17, 2024
Results first posted
Jul 11, 2025
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05328297
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
Jun 3, 2022
Primary completion
May 17, 2024
Completion
May 17, 2024
Results posted
Jul 11, 2025
Last update
Jul 11, 2025

Study contacts

Janssen Pharmaceutica N.V., Belgium Clinical Trial
study director · Janssen Pharmaceutica N.V., Belgium

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JNJ-55308942

Start the discussion